Pharmacology
All Targets
7-TM Receptors
Ion Channels
Nuclear Receptors
Enzyme-Linked Receptors
Transporters
Enzymes
Other Pharmacology
Cellular Processes
Angiogenesis
Apoptosis
Cell Cycle
Cell Metabolism
Cytoskeleton & Motor Proteins
ECM & Adhesion Molecules
Signal Transduction
Stem Cells
Signaling Pathways 
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Adenosine Receptor Data
| Receptor Subtype | A1 | A2A | A2B | A3 |
|---|
| Transduction Mechanism | ↓Adenylyl Cyclase (Gi/o) and ↑ PLC | ↑Adenylyl Cyclase (Gs) | ↑Adenylyl Cyclase (Gs) and ↑ PLC (Gq) | ↓Adenylyl Cyclase (Gi/o) and ↑ PLC |
| Primary Distribution | Brain (cortex, cerebellum, hippocampus), spinal cord, eye, adrenal gland, atria | Spleen, thymus, leukocytes, platelets, striatopallidal GABAergic neurons, olfactory bulb | Cecum, colon, bladder | Testis, mast cells |
| Tissue Function | Antinociception, hypothermia, sedation, sleep, inhibition of lipolysis, cardio- and neuroprotection | Reflex tachycardia, vasodilation, inhibition of platelet aggregation, sleep, protection against ischemia | Relaxation of vascular and intestinal smooth muscle, cytokine production, inhibition of cell proliferation | Mast cell degranulation, coronary vasodilation and protection from reperfusion |
| Key Compounds | Ki Values (nM) |
|---|
| Agonists |
CGS 21680 (1063) 2-Chloro-N6-cyclopentyladenosine (1705) 2-Cl-IB-MECA (1104) N6-Cyclopentyladenosine (1702) HEMADO (1579) IB-MECA (1066) 2'-MeCCPA (2281) NECA (1691) SDZ WAG 994 (2465) |
290 0.8 820 (rat) 2.3 327 3.7 3.3 14 23 |
27 2300 470 (rat) 790 1230 2500 9580 20 - |
88800* 18800* - 18600* 100000* 11000* 37600 2400* 25000 |
67 42 0.33 (rat) 43 1.1 1.2 1150 6.2 - |
| Antagonists |
CGS 15943 (1699) DPCPX (0439) MRS 1220 (1217) MRS 1334 (1385) MRS 1706 (1584) MRS 1754 (2752) MRS 3777 (2403) PSB 36 (2019) SCH 442416 (2463) VUF 5574 (1359) ZM 241385 (1036) 8-(3-Chlorostyryl)caffeine (3306) PSB 1115 (2009) PSB 603 (3198) |
3.5 3.9 305 (rat) > 100000 (rat) 157 403 > 10000 0.12 (rat) 1111 ~ 10000 (rat) 540 28200 > 10000 > 10000 |
4.2 130 52 (rat) > 100000 (rat) 112 503 > 10000 552 (rat) 0.048 > 10000 (rat) 1.4 54 24000 > 10000 |
16 50 - - 1.39 1.97 > 10000 187 > 10000 - 31 - 53.4 0.568 |
51 4000 0.7 5.69 230 570 47 2300 > 10000 4 270 - > 10000 > 10000 |
* EC50 values
References
Klotz et al (2000) Naunyn-Schmied.Arch.Pharmacol. 362 382.Kim et al (1994) J.Med.Chem. 37 3614. van Muijlwijk-Koezen et al (2000) J.Med.Chem. 43 2227. Kim et al (2000) J.Med.Chem. 43 1165. Volpini et al (2002) J.Med.Chem. 45 3271. Li et al (1998) J.Med.Chem. 41 3186. Cappellacci et al (2005) J.Med.Chem. 48 1550. Osama et al (2004) J.Pharmacol.Exp.Ther. 308 358. Toddle et al (2000) J.Med.Chem. 43 4359. Jacobson and Gao (2000) Nat.Rev.Drug Discov. 5 247.